Drug intelligence / Profile preview

PTX-35

Development stage: Discontinued
Lead developer: Heat Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Parenteral (intravenous)

Overview

PTX-35 is a humanized monoclonal antibody that acts as a TNFRSF25 (death receptor 3) agonist. It is designed to modulate the immune system by stimulating antigen-experienced T cells, particularly memory CD8+ T cells, which are crucial for eliminating tumor cells. Initially developed for treating solid tumors and islet cell transplant rejection in type 1 diabetes, its development has been discontinued for these indications.

Targets

DR3 (Tumor necrosis factor receptor superfamily member 25)

Beyond the preview

Go deeper on PTX-35.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTX-35.

Explore the full profile